Patents by Inventor Motoki Sawamura

Motoki Sawamura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTISENSE NUCLEIC ACID TARGETING PCSK9
    Publication number: 20220160880
    Abstract: Provided is an oligonucleotide conjugate comprising an oligonucleotide and two or more linearly connected asialoglycoprotein receptor-binding molecules attached to the oligonucleotide, wherein the oligonucleotide comprises a locked nucleoside analog having a bridging structure between the 4? and 2? positions, is complementary to a human PCSK9 gene, and has inhibitory activity on the expression of the human PCSK9 gene. The oligonucleotide conjugate of the present invention can be used in the field of pharmaceutical products, in particular, the field of the development and production of therapeutic agents for diseases associated with a high LDL cholesterol level.
    Type: Application
    Filed: February 3, 2022
    Publication date: May 26, 2022
    Inventors: Mariko Harada-Shiba, Fumito Wada, Satoshi Obika, Tsuyoshi Yamamoto, Keisuke Tachibana, Tadayuki Kobayashi, Kosuke Ito, Motoki Sawamura
  • Antisense nucleic acid targeting PCSK9
    Patent number: 11273222
    Abstract: Provided is an oligonucleotide conjugate comprising an oligonucleotide and two or more linearly connected asialoglycoprotein receptor-binding molecules attached to the oligonucleotide, wherein the oligonucleotide comprises a locked nucleoside analog having a bridging structure between the 4? and 2? positions, is complementary to a human PCSK9 gene, and has inhibitory activity on the expression of the human PCSK9 gene. The oligonucleotide conjugate of the present invention can be used in the field of pharmaceutical products, in particular, the field of the development and production of therapeutic agents for diseases associated with a high LDL cholesterol level.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: March 15, 2022
    Assignee: National Cerebral and Cardiovascular Center
    Inventors: Mariko Harada-Shiba, Fumito Wada, Satoshi Obika, Tsuyoshi Yamamoto, Keisuke Tachibana, Tadayuki Kobayashi, Kosuke Ito, Motoki Sawamura
  • ANTISENSE NUCLEIC ACID TARGETING PCSK9
    Publication number: 20210170032
    Abstract: Provided is an oligonucleotide conjugate comprising an oligonucleotide and two or more linearly connected asialoglycoprotein receptor-binding molecules attached to the oligonucleotide, wherein the oligonucleotide comprises a locked nucleoside analog having a bridging structure between the 4? and 2? positions, is complementary to a human PCSK9 gene, and has inhibitory activity on the expression of the human PCSK9 gene. The oligonucleotide conjugate of the present invention can be used in the field of pharmaceutical products, in particular, the field of the development and production of therapeutic agents for diseases associated with a high LDL cholesterol level.
    Type: Application
    Filed: May 24, 2018
    Publication date: June 10, 2021
    Inventors: Mariko Harada-Shiba, Fumito Wada, Satoshi Obika, Tsuyoshi Yamamoto, Keisuke Tachibana, Tadayuki Kobayashi, Kosuke Ito, Motoki Sawamura